《Table 1Transcriptomic subtypes of triple-negative breast cancer and potential therapeutic agents》

  提示：宽带有限、当前游客访问压缩模式

本系列图表出处文件名：随高清版一同展现

《Applications of RNA Indexes for Precision Oncology in Breast Cancer》

1. 获取 高清版本忘记账户？点击这里登录

1. 下载图表忘记账户？点击这里登录

Note:Data are obtained from[82].BL，basal-like；IM，immunomodulatory；M，mesenchymal；MSL，mesenchymal stem-like；LAR，luminal androgen receptor；UNS，unstable；PARP，poly（ADP-ribose）polymerase；EMT，epithelial-to-mesenchymal transition；m TOR，mammalian target

Using massively parallel m RNA sequencing，numerous transcripts that are differentially expressed between TNBC and non-TNBC have been identified[83].Based on the comprehensive transcriptomic analysis of 21 breast cancer datasets，Lehmann et al.classify TNBC into seven subtypes[82].These include two basal-like subtypes（BL1 and BL2），an immunomodulatory subtype（IM），a mesenchymal subtype（M），a mesenchymal stem-like subtype（MSL），a luminal androgen receptor subtype（LAR），and an unclassified set that is regarded as unstable（UNS）（Figure 1 and Table 1） .The BL1subtype strongly expresses specific genes that are related to cell proliferation and DNA damage response.It preferentially responds to cisplatin and poly（ADP-ribose）polymerase（PARP）inhibitors.The BL2 subtype is enriched with genes that are associated with growth factor pathways，indicating that growth factor inhibitors may be efficacious for the BL2subtype.The IM subtype possesses abundant genes that are involved in immune-mediated reactions，and programmed cell death 1/programmed death-ligand 1（PD1/PDL1）inhibitors are anticipated to be a hopeful therapeutic option for this subtype.Both the M and MSL subtypes specifically express genes that are relevant to cell motility，cellular differentiation，and growth factor pathways，while the MSL subtype expresses lower levels of proliferation genes than those present in the M subtype.The mammalian target of rapamycin（m TOR）inhibitors and epithelial-to-mesenchymal transition（EMT）-targeted agents are candidate drugs for these two subtypes.The LAR subtype is named for the AR enrichment，and antiandrogen treatments（e.g.，bicalutamide，an AR antagonist）are undergoing clinical trials[82，84，89].